Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
UCB |
---|---|
Information provided by: | UCB |
ClinicalTrials.gov Identifier: | NCT00160511 |
16 week trial assessing the efficacy, safety, and tolerability of levetiracetam compared with placebo in the treatment of postherpetic neuralgia.
Condition | Intervention | Phase |
---|---|---|
Neuralgia, Postherpetic |
Drug: Levetiracetam |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia |
Estimated Enrollment: | 170 |
Study Start Date: | April 2004 |
Study Completion Date: | September 2005 |
Primary Completion Date: | August 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | N01087 |
Study First Received: | September 8, 2005 |
Last Updated: | March 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00160511 |
Health Authority: | United States: Food and Drug Administration |
Postherpetic Neuralgia (PHN) Levetiracetam Keppra Nerve Pain |
Neuralgia, Postherpetic Signs and Symptoms Neuromuscular Diseases Neuralgia Peripheral Nervous System Diseases |
Piracetam Neurologic Manifestations Etiracetam Pain |
Nootropic Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases Protective Agents |
Neuroprotective Agents Central Nervous System Agents Pharmacologic Actions Anticonvulsants |